Breast Cancer Core Needle Biopsy (CNB) Market Analysis

Breast Cancer Core Needle Biopsy Market Analysis

To get key market trends

  Download Free Sample

Based on image-guidance technology, the market is segmented into stereotactic-guided, ultrasound-guided, and magnetic resonance imaging (MRI)-guided. The ultrasound-guided segment dominated the market and is anticipated to grow at 7.6% CAGR over the forecast period.
 

• Ultrasound-guided CNB's dominance was asserted due to its high accuracy and non-invasive nature. This technique uses real-time ultrasound imaging to precisely locate and target suspicious breast tissue, ensuring that the biopsy samples are obtained from the exact area of concern.
   
• Additionally, its advantages include reduced procedure time, minimal discomfort for patients, and immediate visualization of the biopsy site, all of which contribute to its widespread adoption.
   
• Moreover, its cost-effectiveness and ease of integration into clinical practice have further bolstered its dominance in the breast cancer core needle biopsy (CNB) market.
   

Based on the end-user, the breast cancer core needle biopsy market is categorized into hospitals, cancer research centers, diagnostic centers, and research & academics. The hospitals segment accounted for the highest market share of 48.4% in 2023.
 

• The hospital's dominance was attributed to its comprehensive diagnostic capabilities and advanced facilities. Hospitals offer a range of imaging technologies, such as ultrasound and mammography, integrated with biopsy procedures, ensuring high accuracy and patient care standards.
   
• These facilities also benefit from their capacity to handle complex cases, provide specialized medical teams, and offer follow-up care, enhancing the overall diagnostic process.
   
• Furthermore, their large patient volumes and established infrastructure contribute to the dominance of hospitals in the core needle biopsy (CNB) market, driving widespread adoption and consistent use of these diagnostic procedures.
   

U.S. breast cancer CNB market size accounted for USD 320.3 million in 2023.
 

• The U.S. holds a prominent position largely due to several key factors, such as the high incidence of breast cancer and the increased demand for effective diagnostic procedures.
   
• For instance, according to the American Cancer Society, about 1 in 8 women, or approximately 13% of the female population in the U.S., will develop breast cancer in their lifetime. In 2024, it is estimated that breast cancer will account for around 30% of all new female cancer diagnoses. This underscores the critical need for effective diagnostic tools and procedures to manage and treat the disease promptly, thereby augmenting market demand.
   
• Additionally, continuous technological advancements in biopsy devices and favorable reimbursement policies further support market growth.
   

Germany holds a prominent position in the European breast cancer core needle biopsy market.
 

• Germany's prominence in the European breast cancer core needle biopsy (CNB) market is attributed to its advanced healthcare infrastructure and leading-edge diagnostic technologies. The country’s robust medical research environment and high standards of patient care drive the adoption of innovative CNB techniques.
   
• In addition, a strong focus on early detection and precision in breast cancer diagnosis, supported by advanced imaging systems and skilled medical professionals, contributes to its leadership in the market.
   
• Moreover, strong government support for healthcare advancements and widespread access to advanced diagnostic tools further solidify Germany's position as a key player in the European market.
   

Asia Pacific breast cancer core needle biopsy market is poised for rapid growth with a CAGR of 8.2% during the forecast period.
 

• Asia Pacific is poised for rapid growth due to the increasing incidence of breast cancer, expanding healthcare infrastructure, and rising awareness about early detection.
   
• Improved access to advanced diagnostic technologies and growing investments in medical facilities are enhancing the availability of CNB procedures.
   
• Moreover, government initiatives and public health campaigns are promoting regular screenings. As a result, the region's diverse and large population, coupled with advancements in imaging techniques, is driving significant market expansion and the adoption of CNB as a preferred method for accurate breast cancer diagnosis.